SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Smedby Karin) "

Sökning: WFRF:(Smedby Karin)

  • Resultat 1-10 av 196
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Smedby, Karin E., et al. (författare)
  • The National Swedish Lymphoma Register - a systematic validation of data quality
  • 2024
  • Ingår i: Acta Oncologica. - : Medical Journals Sweden. - 0284-186X .- 1651-226X. ; 63, s. 563-572
  • Tidskriftsartikel (refereegranskat)abstract
    • Background and purpose: The Swedish Lymphoma Register (SLR) was initiated in the year 2000 with the aim to monitor quality of care in diagnostics, treatment and outcome of all lymphomas diagnosed nationally among adults. Here, we present the first systematic validation of SLR records as a basis for improved register quality and patient care.Patients and methods: We evaluated timeliness and completeness of register records among patients diagnosed with lymphoma in the SLR (n n = 16,905) compared with the National Cancer Register for the period 2013-2020. Comparability was assessed through evaluation of coding routines against national and international guidelines. Accuracy of 42 variables was evaluated through re-abstraction of data from medical records among 600 randomly selected patients diagnosed in 2016-2017 and treated across all six Swedish healthcare regions.Results: Completeness was high, >95% per year for the period 2013-2018, and >89% for 2019-2020 compared to the National Cancer Register. One in four patients was registered within 3 months, and 89.9% within 2 years of diagnosis. Registration instructions and coding procedures followed the prespecified guidelines. Missingness was generally low (<5%), but high for occasional variables, for example, those describing maintenance and consolidative treatment. Exact agreement of categorical variables was high overall (>80% for 24/34 variables), especially for treatment-related data (>80% for 17/19 variables).Interpretation: Completeness and accuracy are high in the SLR, while timeliness could be improved. Finetuning of variable registration guided by this validation can further improve reliability of register reports and advance service to lymphoma patients and health care in the future.
  •  
2.
  • Cordtz, Rene Lindholm, et al. (författare)
  • Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors : a Nordic cohort study
  • 2022
  • Ingår i: RMD Open. - : BMJ Publishing Group Ltd. - 2056-5933. ; 8:2
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives To evaluate the risk of haematological malignancies in patients with psoriatic arthritis (PsA) overall, and in relation to treatment with tumour necrosis factor inhibitors (TNFi).Methods We identified that patients with PsA starting a first TNFi from the clinical rheumatology registers (CRR) in the five Nordic countries (n=10 621) and biologics-naive PsA patients from (1) the CRR (n=18 705) and (2) the national patient registers (NPR, n=27 286, Sweden and Denmark) from 2006 through 2019. For Sweden and Denmark, general population comparators were matched 5:1 to PsA patients on birth year, year at start of follow-up and sex. By linkage to the national cancer registers in all countries, we collected information on haematological malignancies overall, and categorised into lymphoid or myeloid types. We estimated incidence rate ratios (IRRs) with 95% CIs using modified Poisson regression for TNFi-treated versus biologics-naive PsA patients and versus the general population adjusted for age, sex, calendar period and country.Results During 59 827 person-years, 40 haematological malignancies occurred among TNFi-treated patients with PsA resulting in a pooled IRR of 0.96 (0.68-1.35) versus biologics-naive PsA from CRR and an IRR of 0.84 (0.64-1.10) versus biologics-naive PsA from NPR. The IRR of haematological malignancies in PsA overall versus general population comparators was 1.35 (1.17-1.55). The estimates were largely similar for lymphoid and myeloid malignancies.Conclusions Treatment with TNFi in patients with PsA was not associated with an increased incidence of haematological malignancies. Conversely, a moderately increased underlying risk was seen in patients with PsA compared with the general population.
  •  
3.
  • Eloranta, Sandra, et al. (författare)
  • Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013
  • 2018
  • Ingår i: European Journal of Haematology. - : WILEY. - 0902-4441 .- 1600-0609. ; 100:1, s. 61-68
  • Tidskriftsartikel (refereegranskat)abstract
    • Objectives: This study aims to characterize the epidemiology of immunocompetent Primary central nervous system lymphoma (PCNSL) diagnosed 2000-2013 in Sweden.Methods: Cases were identified in the population-based Swedish Lymphoma Register. Incidence per 100000 person-years and 95% confidence intervals (CI) were calculated, and PCNSL-specific survival was estimated using relative survival. Tests for temporal trends were performed using Poisson regression. Population incidence of all brain tumors was retrieved for comparison.Results: With 359 identified PCNSL cases (median age 66years), overall incidence was 0.26 (95% CI: 0.24-0.29) and the average annual increase 4% (P=.002). The increasing trend was primarily observed among elderly individuals (70+years). Similarly, an increase in incidence of all brain tumors was noted only among the elderly. There was no significant improvement in relative survival across the study period although, among fit patients (with Eastern Cooperative Oncology Group, EGOC 0), survival plateaued 6years after diagnosis.Conclusion: The increasing PCNSL incidence in the elderly was consistent with an increasing incidence of brain tumors of any type and may in part be attributable to improved diagnostics and reporting in this group. New treatment options have not yet translated into general survival improvements in a population-based setting, although the presence of long-term survivors among fit patients is encouraging.
  •  
4.
  •  
5.
  • Everhov, Åsa H, et al. (författare)
  • Serum Androgen Levels and Sexual Function Before and One Year After Treatment of Uterine Cervical Cancer: A Pilot Study.
  • 2016
  • Ingår i: The journal of sexual medicine. - : Oxford University Press (OUP). - 1743-6109 .- 1743-6095. ; 13:3, s. 413-24
  • Tidskriftsartikel (refereegranskat)abstract
    • Radiotherapy or radical hysterectomy with salpingo-oophorectomy (SOE) as treatment for uterine cervical cancer causes estrogen deprivation in premenopausal women. The effects on androgen production have rarely been examined but could be relevant for survivors of cervical cancer because insufficiency has been associated with low sexual function.
  •  
6.
  •  
7.
  • Forsgren, Elin, et al. (författare)
  • Evaluation of coverage, generalisability and validity of the U-CAN lymphoma biobank in Sweden : a comparison with nationwide registers
  • 2024
  • Ingår i: British Journal of Haematology. - : John Wiley & Sons. - 0007-1048 .- 1365-2141.
  • Tidskriftsartikel (refereegranskat)abstract
    • Validation of biobanks and large cancer cohorts is essential in ensuring high-quality research results. We examined the coverage, generalisability and validity of the lymphoma collection of the Uppsala-Umeå Comprehensive Cancer Consortium (U-CAN) biobank in Sweden, one of the largest cancer biobanks in Europe. Up until 2022, 889 lymphoma patients in U-CAN Uppsala had available samples, and 329 in U-CAN Umeå. Patients diagnosed in the U-CAN Uppsala area 2011–2021 (n = 843) were linked to the nationwide Swedish Lymphoma Register, and a subset diagnosed before 2019 (n = 727) to population-based registers. The coverage was 39% of all lymphoma patients between 2011 and 2019 diagnosed in the U-CAN Uppsala area, with a pandemic decline to 10% during 2020–2021. The patients included had superior overall survival (hazard ratio = 0.70 [95% confidence interval, CI: 0.60–0.82]) than all lymphoma patients in Sweden. They had better performance status, were younger (odds ratio [OR] = 0.21 [95% CI: 0.13–0.34]) and had less comorbidities (OR = 0.66 [95% CI: 0.56–0.78]). However, cause-specific survival and stage distribution were similar. The questionnaire data captured less comorbidities compared to the national registers. Evaluations of biobanks are important, as even population-based biobanks such as U-CAN select younger patients with higher socioeconomical status and better performance status. However, the similar cause-specific survival as in the registries suggests U-CANs usefulness for prognostic biomarker studies.
  •  
8.
  • Gunnarsson, Rebeqa, et al. (författare)
  • Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia
  • 2011
  • Ingår i: Haematologica. - : Ferrata Storti Foundation (Haematologica). - 1592-8721 .- 0390-6078. ; 96:8, s. 1161-1169
  • Tidskriftsartikel (refereegranskat)abstract
    • Background High-resolution genomic microarrays enable simultaneous detection of copy-number aberrations such as the known recurrent aberrations in chronic lymphocytic leukemia [del(11q), del(13q), del(17p) and trisomy 12], and copy-number neutral loss of heterozygosity. Moreover, comparison of genomic profiles from sequential patients' samples allows detection of clonal evolution. Design and Methods We screened samples from 369 patients with newly diagnosed chronic lymphocytic leukemia from a population-based cohort using 250K single nucleotide polymorphism-arrays. Clonal evolution was evaluated in 59 follow-up samples obtained after 5-9 years. Results At diagnosis, copy-number aberrations were identified in 90% of patients; 70% carried known recurrent alterations, including del(13q) (55%), trisomy 12 (10.5%), del(11q) (10%), and del(17p) (4%). Additional recurrent aberrations were detected on chromosomes 2 (1.9%), 4 (1.4%), 8 (1.6%) and 14 (1.6%). Thirteen patients (3.5%) displayed recurrent copy-number neutral loss of heterozygosity on 13q, of whom 11 had concurrent homozygous del(13q). Genomic complexity and large 13q deletions correlated with inferior outcome, while the former was linked to poor-prognostic aberrations. In the follow-up study, clonal evolution developed in 8/24 (33%) patients with unmutated IGHV, and in 4/25 (16%) IGHV-mutated and treated patients. In contrast, untreated patients with mutated IGHV (n=10) did not acquire additional aberrations. The most common secondary event, del(13q), was detected in 6/12 (50%) of all patients with acquired alterations. Interestingly, aberrations on, for example, chromosome 6q, 8p, 9p and 10q developed exclusively in patients with unmutated IGHV. Conclusions Whole-genome screening revealed a high frequency of genomic aberrations in newly diagnosed chronic lymphocytic leukemia. Clonal evolution was associated with other markers of aggressive disease and commonly included the known recurrent aberrations.
  •  
9.
  • Hallqvist Everhov, Asa, et al. (författare)
  • Anti-Müllerian hormone in premenopausal women following treatment of uterine cervical cancer.
  • 2014
  • Ingår i: Acta obstetricia et gynecologica Scandinavica. - : Wiley. - 1600-0412 .- 0001-6349. ; 93:9, s. 949-53
  • Tidskriftsartikel (refereegranskat)abstract
    • In this longitudinal study we prospectively enrolled 32 premenopausal women (ages 23-44years) with stage I-III uterine cervical cancer undergoing surgery and/or chemoradiation. Serum levels of anti-Müllerian hormone, follicle-stimulating hormone and estradiol were examined at baseline and 1year after treatment. As expected, serum anti-Müllerian hormone was undetectable after salpingo-oophorectomy or chemoradiation. After radical hysterectomy and pelvic lymphadenectomy with ovarian preservation serum anti-Müllerian hormone declined from a mean value of 2.0±1.4μg/L to 1.1±0.8μg/L (p=0.01), representing a 45% reduction, whereas there was no significant change in serum levels of follicle-stimulating hormone and estradiol. This implies that ovarian function may be affected not only by castrating treatment but also by radical hysterectomy with ovarian preservation. The risk of premature menopause and the potential need of hormone replacement therapy among these women may be overlooked since they no longer menstruate.
  •  
10.
  • Hellgren, Karin, et al. (författare)
  • Do rheumatoid arthritis and lymphoma share risk factors? : A comparison of lymphoma and cancer risks before and after diagnosis of rheumatoid arthritis
  • 2010
  • Ingår i: Arthritis and Rheumatism. - : Wiley. - 0004-3591 .- 1529-0131. ; 62:5, s. 1252-1258
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: Patients with rheumatoid arthritis (RA), in particular those with the most severe disease, are at increased risk of malignant lymphoma. Whether this increase is entirely consequential to the RA disease and/or its treatment or reflective of shared susceptibility to the two diseases remains unclear. To resolve this, we assessed whether patients with RA are at increased risk of lymphoma or of other cancers, already before diagnosis of RA, and if the relative risk increases with time since RA diagnosis.METHODS: 6,745 patients with incident RA (ACR criteria, symptom duration < 1 year) registered in the Swedish Early RA register from 1997 through 2006 were identified. For each patient, five general population controls were randomly matched by gender, age, marital status and residence (n=33,657). All individuals were linked to the nationwide Swedish Cancer Register 1958-2006. Relative risks (RR) of lymphoma and cancer overall before and after the diagnosis of RA were estimated using conditional logistic and Cox regression, respectively.RESULTS: Before diagnosis of RA, no increased risk of lymphoma (RR= 0.67, 95% CI 0.37-1.23) or other cancers (RR= 0.78, 95% CI 0.70-0.88) was observed. During the first ten years following diagnosis of RA, the overall RR of lymphoma was 1.75 (95 % CI 1.04-2.96).CONCLUSION: Overall, a history of cancer, lymphoma included, does not increase the risk of subsequent RA development. Shared susceptibility for RA and lymphoma may thus be of limited importance. By contrast increased lymphoma risks were observed already within the first decade following RA diagnosis.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-10 av 196
Typ av publikation
tidskriftsartikel (179)
annan publikation (6)
konferensbidrag (5)
forskningsöversikt (4)
doktorsavhandling (2)
Typ av innehåll
refereegranskat (176)
övrigt vetenskapligt/konstnärligt (20)
Författare/redaktör
Smedby, Karin E. (132)
Hjalgrim, Henrik (56)
Glimelius, Bengt (44)
Adami, Hans Olov (41)
Melbye, Mads (39)
Glimelius, Ingrid, 1 ... (35)
visa fler...
Eloranta, Sandra (35)
Juliusson, Gunnar (35)
Rosenquist, Richard (35)
Mansouri, Larry (28)
Chang, Ellen T. (28)
Smedby, Karin Ekströ ... (22)
Ekström-Smedby, Kari ... (21)
Jerkeman, Mats (20)
Enblad, Gunilla (20)
Rostgaard, Klaus (19)
Sutton, Lesley-Ann (18)
Askling, Johan (18)
Ekberg, Sara (17)
Stamatopoulos, Kosta ... (17)
Ghia, Paolo (16)
Pospisilova, Sarka (16)
Conde, Lucia (16)
Skibola, Christine F ... (16)
Cerhan, James R. (16)
Davi, Frederic (15)
Langerak, Anton W. (15)
Brennan, Paul (15)
Bracci, Paige M (15)
Foretova, Lenka (15)
Becker, Nikolaus (15)
Rothman, Nathaniel (15)
Lan, Qing (15)
Plevova, Karla (15)
Benavente, Yolanda (15)
Maynadie, Marc (15)
Nieters, Alexandra (15)
Staines, Anthony (15)
Sundström, Christer (14)
Ekbom, Anders (14)
Belessi, Chrysoula (14)
Spinelli, John J. (14)
Weibull, Caroline E (14)
Cozen, Wendy (14)
de Sanjose, Silvia (14)
Purdue, Mark P. (14)
Slager, Susan L. (14)
Vajdic, Claire M. (14)
Zhang, Yawei (14)
Zheng, Tongzhang (14)
visa färre...
Lärosäte
Karolinska Institutet (179)
Uppsala universitet (149)
Lunds universitet (60)
Örebro universitet (22)
Umeå universitet (19)
Linköpings universitet (12)
visa fler...
Göteborgs universitet (6)
Kungliga Tekniska Högskolan (2)
Stockholms universitet (2)
Jönköping University (1)
visa färre...
Språk
Engelska (196)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (167)
Naturvetenskap (4)
Teknik (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy